期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

朗格汉斯细胞组织细胞增生症治疗进展 被引量：6

Progress in the treatment of Langerhans cell histiocytosis
下载PDF
导出
摘要 目前朗格汉斯细胞组织细胞增生症(LCH)在治疗上采用分型、分级而分治的策略。研究表明,单系统病变(SS-LCH)的预后好,而伴危险器官受累的多系统病变(MS-LCH)及难治性/复发性病例(Re-LCH)预后差。随着化学疗法的进步,伴危险器官受累的MS-LCH 5年生存率已达80%以上,Re-LCH的治疗有效率达60%以上,Re-LCH可行造血干细胞移植以达到根治。 Treatment of Langerhans cell histiocytosis（LCH） needs to be tailored for each individual patient according to LCH classification currently.Single-system LCH（SS-LCH） has an excellent prognosis.However,there is a poor prognosis in multisystem LCH（MS-LCH） with risk organs（RO） involvement and refractory or recurrent LCH（Re-LCH）.The prognosis of MS-LCH with RO involvement and Re-LCH has been improved markedly accompanying with progress of chemotherapy in recent years.The 5-year survival rate of MS-LCH reached above 80%,and the effective rate of Re-LCH reached above 60% after chemotherapy.Re-LCH can be cured by hematopoietic stem cell transplantation.
作者 泥永安 孙立荣
机构地区 青岛大学附属医院儿科
出处 《临床儿科杂志》 CAS CSCD 北大核心 2015年第3期291-294,共4页 Journal of Clinical Pediatrics
关键词 朗格汉斯细胞组织细胞增生症 单系统病变 多系统病变 治疗 Langerhans cell histiocytosis single-system LCH multisystem LCH therapy
分类号 R597 [医药卫生—内科学]
  • 相关文献

参考文献29

  • 1Haupt R, Minkov M, Astigarraga I, et al. Langerhans cell his-tiocytosis (LCH):guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years [J]. Pediatr Blood Cancer, 2013, 60(2):175-184.
  • 2Egeler RM, Thompson RC, Voute PA, et al. Intralesional infiltra-tion of cortieosteroids in localized Langerhans ' cell histiocytosis [J]. J Pediatr Orthop, 1992, 12(6):811-814.
  • 3MorimotoA, Ikushima S, KinugawaN, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocy-tosis:results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study [J]. Cancer, 2006, 107(3):613-619.
  • 4Ng Wing Tin S, Martin-Duvemeuil N, Idbaih A, et al. Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis:a nationwide retrospective study [J]. Orphanet J Rare Dis, 2011, 6:83.
  • 5Dhall G, Finlay JL, Dunkel IJ, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine [J]. Pediatr Blood Cancer, 2008, 50(1):72-79.
  • 6Imashuku S, Kinugawa N, Matsuzaki A, et al. Langerhans cell histiocytosis with multifocal bone lesions:comparative clinical fea-tures between single and multi-systems [J]. Int J Hematol, 2009, 90(4):506-512.
  • 7Shioda Y, Adachi S, Imashuku S, et al. Analysis of 43 cases of Langerhans cell histiocytosis (LCH)-induced central diabetes insi-pidus registered in the JLSG-96 and JLSG-02 studies in Japan [J].Int J Hematol, 2011, 94(6):545-551.
  • 8Ottaviano F, Finlay JL. Diabetes insipidus and Langerhans cell histiocytosis:a case report of reversibility with 2-chlorodeoxyade-nosine [J]. J Pediatr Hematol Oncol, 2003, 25(7):575-577.
  • 9Schonfeld N, Dirks K, Costabel U, et al. A prospective clinical multicentre study on adult pulmonary Langerhans' cell histioeyto-sis [J]. Sarcoidosis Vase Diffuse Lung Dis, 2012, 29(2):132-138.
  • 10Ng-Cheng-Hin B, O'hanlon-brown C, Alifrangis C, et al. Lang-erhans cell histioeytosis:old disease new treatment [J]. QJM, 2011, 104(2):89-96.

二级参考文献18

  • 1Grois N, Potschger U, Prosch H, et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer, 2006 ;46 ( 2 ) :228 - 233.
  • 2Alston RD, Tatevossian RG, McNally RJ, et al. Incidence and survival of childhood langerhans cell histiocytosis in northwest england from 1954 to 1998.Pediatr Blood Cancer,2007 ; 48 ( 5 ) : 555 - 560.
  • 3Daniel P, Guadalupe R, Antonio L, et al. Reactivation and risk of sequelae in langerhans cell histiocytosis. Pediatr Blood Cancer, 2007 ; 48 ( 7 ) : 696 - 699.
  • 4Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis. Results from the Japan Langerhans cell histiocytosis study group-96 protocol. Cancer,2006; 107 (3) :613 - 619.
  • 5Writing Group of Histiocyte Society. Histiocytosis syndrome in children. Lancet, 1987 ; 1 ( 8526 ) :208 - 209.
  • 6Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytic disorders. The WHO committee on histiocytic/ reticulum cell proliferations. Reclassification working group of the Histiocyte Society. Med Pediatr Oncol, 1997 ; 29 (3) : 157 - 166.
  • 7Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am, 1998;12 (2) :327 - 338.
  • 8Minkov M, Grois N, Heitger A, et aL Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL- HX 90 studies. DAL-HX Study Group. Klin Padiatr, 2000; 212 (4) : 139 - 144.
  • 9Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans cell histiocytosis. J Pediatr, 2001; 138 (5) ; 728 -734.
  • 10Haupt R, Fears TR, Heise A, et al. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans cell histiocytosis in Italian and Austrian-German populations. Int J Cancer, 1997 ; 71 ( 1 ) : 9 - 13.

共引文献6

同被引文献33

引证文献6

二级引证文献14

临床儿科杂志
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部